Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;106(6):1310-1318.
doi: 10.1002/cpt.1534. Epub 2019 Jul 22.

Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention

Meghan E Whalen  1 , Richard Kajubi  2   3 , Nona Chamankhah  4 , Liusheng Huang  1 , Francis Orukan  2 , Erika Wallender  5 , Moses R Kamya  2 , Grant Dorsey  5 , Prasanna Jagannathan  6 , Philip J Rosenthal  5 , Norah Mwebaza  2   3 , Francesca T Aweeka  1
Affiliations

Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention

Meghan E Whalen et al. Clin Pharmacol Ther. 2019 Dec.

Abstract

Dihydroartemisinin (DHA)-piperaquine is being evaluated as intermittent preventive therapy for malaria, but dosing has not been optimized for children. We assessed exposure to DHA and piperaquine in Ugandan children at two ages during infancy. Intensive sampling was performed in 32 children at 32 weeks of age, 31 children at 104 weeks, and 30 female adult controls. Compared with adults, DHA area under the concentration-time curve (AUC0-8 hr ) was 52% higher at 32 weeks and comparable at 104 weeks. Compared with adults, piperaquine AUC0-21 d was 35% lower at 32 weeks and 53% lower at 104 weeks. Terminal piperaquine concentrations on days 7, 14, and 21 were lower in children compared with adults and lower at 104 compared with 32 weeks. Piperaquine exposure was lower in young children compared with adults, and lower at 104 compared with 32 weeks of age, suggesting a need for age-based DHA-piperaquine dose optimization for chemoprevention.

Trial registration: ClinicalTrials.gov NCT02163447.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: The authors declared no competing interests for this work.

Figures

Figure 1.
Figure 1.
Enrollment and completion of intensive PK studies from trials evaluating DHA- piperaquine as IPTi for malaria; DP denotes DHA-piperaquine; SP, sulfadoxine-pyrimethamine; PK, pharmacokinetics; DHA, dihydroartemisinin; PQ, piperaquine. *Adult data previously reported (14).
Figure 2.
Figure 2.
Plasma concentration-time profile of DHA (A) and piperaquine (B) in children aged 104 weeks (black line) and 32 weeks (red line) and postpartum women (green line). Data is reported as median (IQR).
Figure 3.
Figure 3.
Correlation of changes in the QTcB interval and pharmacokinetic exposure of piperaquine. AUC denotes area under the concentration vs. time curve to 21 days.
See this image and copyright information in PMC

References

    1. World Health Organization. (2018). World Malaria Report 2018 (https://www.who.int/malaria/media/world-malaria-report-2018/en/, 2018).
    1. Walker PG, ter Kuile FO, Garske T, Menendez C & Ghani AC Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Health 2, e460–7 (2014). - PubMed
    1. Steketee RW, Nahlen BL, Parise ME & Menendez C The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64, 28–35 (2001). - PubMed
    1. World Health Organization. Intermittent preventive treatment in pregnancy (IPTp). <https://www.who.int/malaria/areas/preventive_therapies/pregnancy/en/> (2018). Accessed January 31 2019.
    1. World Health Organization. Seasonal malaria chemoprevention (SMC). <https://www.who.int/malaria/areas/preventive_therapies/children/en/> (2017). Accessed January 31 2019.

Publication types

Associated data